• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

More than the prostate: Intrapancreatic accessory spleen and papillary thyroid cancer detected with F-PSMA PET/CT.

作者信息

Singh Dalveer, Horneman Roslyn, Nagra Navjot Kaur

机构信息

Qscan Radiology Clinics (QLD), 123 Nerang Street Southport, Queensland, 4215, Australia.

出版信息

Hell J Nucl Med. 2018 May-Aug;21(2):145-147. doi: 10.1967/s002449910805. Epub 2018 Jul 12.

DOI:10.1967/s002449910805
PMID:30006647
Abstract

OBJECTIVE

Prostate specific membrane antigen (PSMA) positron emission tomography diagnostic computed tomography (PET/CT) is gaining an increasing role in the staging of prostate cancer and restaging in cases of biochemical recurrence. Our understanding of PSMA affinity for incidental pathological and non-pathological entities is also maturing although certain cases do present as diagnostic and management dilemmas.

SUBJECT AND METHODS

We present a case of a 55 years old man with prostate adenocarcinoma, with incidentally found pancreatic and thyroid lesions showing PSMA avidity.

RESULTS

We were able to utilize a heat damaged red blood cell single photon emission tomography (SPET)/CT scan and ultrasound guided fine needle aspiration (FNA) to accurately diagnose co-existent thyroid papillary carcinoma and intra-pancreatic accessory spleen (IPAS) tissue, respectively. The patient avoided invasive pancreatic tissue sampling and subsequent staging with fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT.

CONCLUSION

This is the first case to our knowledge describing both such lesions in one patient and the first case describing the use of 2-(3-{1-carboxy-5-[(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (F-DCFPyL)-PSMA PET/CT to detect IPAS. Furthermore we highlight the value of nuclear medicine diagnostic work up in complex cases.

摘要

相似文献

1
More than the prostate: Intrapancreatic accessory spleen and papillary thyroid cancer detected with F-PSMA PET/CT.
Hell J Nucl Med. 2018 May-Aug;21(2):145-147. doi: 10.1967/s002449910805. Epub 2018 Jul 12.
2
Prospective Comparison of PET Imaging with PSMA-Targeted F-DCFPyL Versus NaF for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.PSMA 靶向 F-DCFPyL PET 显像与 NaF 用于检测转移性前列腺癌骨转移病灶的前瞻性比较。
J Nucl Med. 2020 Feb;61(2):183-188. doi: 10.2967/jnumed.119.227793. Epub 2019 Aug 26.
3
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on F-DCFPyL PET/CT Imaging.PSMA-RADS 1.0 标准化报告系统在 F-DCFPyL PET/CT 成像中的观察者间一致性。
J Nucl Med. 2018 Dec;59(12):1857-1864. doi: 10.2967/jnumed.118.217588. Epub 2018 Sep 6.
4
The prostate-specific membrane antigen (PSMA)-targeted radiotracer F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.前列腺特异性膜抗原(PSMA)靶向放射性示踪剂 F-DCFPyL 可检测转移性、晚期、放射性碘难治性、分化型甲状腺癌中的肿瘤新生血管。
Med Oncol. 2020 Oct 9;37(11):98. doi: 10.1007/s12032-020-01427-0.
5
PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?前列腺特异性膜抗原在甲状腺乳头状癌中的表达:为甲状腺癌的治疗开辟新视野?
Clin Nucl Med. 2016 May;41(5):e263-5. doi: 10.1097/RLU.0000000000001148.
6
Intraindividual Comparison of F-PSMA-1007 and F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.个体内比较 F-PSMA-1007 和 F-DCFPyL PET/CT 在新诊断前列腺癌患者中的前瞻性评估:一项初步研究。
J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21.
7
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.2-(3-{1-羧基-5-[(6-[18F]氟吡啶-3-羰基)-氨基]-戊基}-脲基)-戊二酸,[18F]DCFPyL,一种用于前列腺癌的 PSMA 基 PET 成像剂。
Clin Cancer Res. 2011 Dec 15;17(24):7645-53. doi: 10.1158/1078-0432.CCR-11-1357. Epub 2011 Oct 31.
8
An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application.一种 F 型 PSMA 配体用于前列腺癌的 PET/CT:F-JK-PSMA-7 在应用的第一年中的首例人体观察性研究和临床经验。
J Nucl Med. 2020 Feb;61(2):202-209. doi: 10.2967/jnumed.119.229542. Epub 2019 Jul 19.
9
The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.谷氨酸单钠对复发性前列腺癌患者 PSMA 放射性示踪剂摄取的影响:一项前瞻性、随机、双盲、安慰剂对照个体内成像研究。
J Nucl Med. 2021 Jan;62(1):81-87. doi: 10.2967/jnumed.120.246983. Epub 2020 May 8.
10
F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria.F-DCFPyL PET/CT 用于前列腺癌亚临床复发患者:病灶大小、平滑滤波器和部分容积校正对 PROMISE 标准的影响。
J Nucl Med. 2020 Nov;61(11):1615-1620. doi: 10.2967/jnumed.120.241737. Epub 2020 Mar 20.

引用本文的文献

1
Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer.用于改善分化型甲状腺癌检测的正电子发射断层显像示踪剂的研发进展
Cancers (Basel). 2024 Apr 2;16(7):1401. doi: 10.3390/cancers16071401.
2
Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.正电子发射断层扫描放射性药物在分化型甲状腺癌中的应用。
Molecules. 2022 Aug 3;27(15):4936. doi: 10.3390/molecules27154936.
3
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.
PSMA 放射性配体疗法治疗除前列腺癌以外的实体瘤:背景、机遇、挑战和初步临床报告。
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368. doi: 10.1007/s00259-021-05433-w. Epub 2021 Jun 12.
4
Laparoscopic spleen-preserving pancreatic resection for intrapancreatic accessory spleen: Case report.腹腔镜保留脾脏的胰腺内副脾切除术:病例报告
Medicine (Baltimore). 2019 Aug;98(31):e16488. doi: 10.1097/MD.0000000000016488.